This work aims at assessing and describing the most frequent clinical manifestations of the Graft-versus-
Host Disease (GvHD) in the oral and maxillofacial region in paediatric patients affected by neoplastic or non neoplastic
haematologic disorders who undergo specific haematopoietic stem cell transplantation (HSCT) protocols, with a view to
detecting the potential pathological modifications that are recognised as the cause of a possible altered harmonious
development of the child.
Thirty-eight paediatric patients aged between 3 and 13 years,
coming from the haematological department of Tor Vergata University (Roma, Italy) and affected by GvHD, assessed on the
basis of their medical history and accurate clinical and instrumental exams, after having received haematopoietic stem cell
transplantation for neoplastic or non neoplastic haematologic disorders, were enrolled in this study. The aim of this work
was to assess oral conditions, detect possible oral pathological manifestations and evaluate their incidence both locally and
in terms of clinical severity, as well as to mitigate associated symptoms. This was done to prevent and eliminate any oral
interference in the systemic treatment protocol. DISCUSSION AND
In line with the data presented in the
literature, clinical GvHD manifestations seem to mainly involve the oral and maxillofacial region from an early phase also in
paediatric patients. As a consequence, a timely diagnosis and a multidisciplinary treatment programme are essential for the
early detection of the oral signs of potential systemic complications, to improve the quality of life of these young patients, as
well as to prevent any potential alterations of dentoskeletal development and growth in the child.
Vol.12 – n.1/2011
Harvard: R. Cond, P. Maturo, C. Perugia, R. Docimo (2011) "Oral lesions in paediatric patients with graft-versushost disease", European Journal of Paediatric Dentistry, 12(1), pp50-54. doi:
Copyright (c) 2021 Ariesdue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.